Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 399-402

  Landry, P ^a   Tremblay, S ^a   Darioli, R ^a   Genton, B ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Booster; Hepatitis A; Traveler; Vaccine

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRAVEL;

ADULT; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATOVIRUS; HUMAN; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; TRAVEL; VACCINES, INACTIVATED;

EID: 0034668150     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00188-2     Document Type: Article

References (14)

1. Iwarson S. What type of travelers would benefit from combined vaccination against hepatitis A and B? J. Travel Med. 5:1998;80-83.
2. Wiedermann G., Kundi M., Ambrosch F. Estimated persistence of anti-HAV antibodies after single and booster hepatitis A vaccination (0-6 schedule). Acta Tropica. 69:1998;121-125.
3. André F.E. Hepatitis A vaccine: current status and future use. Rizzetto M, Purcell R.H., Gerin J.L., Verme G. Viral hepatitis and liver disease. 1997;624-626.
4. Van Damme P., Mathei C., Thoelen S., Meheus A., Safary A., André F.E. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J. Med. Virol. 44:1994;435-441.
5. Van Heck K., van Damme P., Thoelen S. A high potency inactivated hepatitis A vaccine: long term follow-up. 6th Conference International Society of Travel Medicine. Montreal, June :1999.
6. Van Damme P., Thoelen S., Cramm M., de Groote K., Safary A., Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J. Med. Virol. 44:1994;446-451.
7. Cederna J.B., Klinzman D., Stapleton J.T. Inactivated hepatitis A vaccine ellicits HAV-specific T cell proliferation. IX Triennal International Symposium on Viral Hepatitis and Liver Disease, Rome April. 1996;. [Abstract A78].
8. Schmidtke P., Habermehl P., Knuf M., Meyer C.U., Slaoui M., Safary A., Clemens R., Zepp F. Kinetics of hepatitis A virus (HAV) specific humoral and cell mediated immunity after vaccination. 35th ICAAC. 1997;. [Abstract 586].
9. Wiström J., Ahlm C., Lundberg S., Settergren B., Tärnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine. 17:1999;2162-2165.
10. Goubau P., van Gerven, V., Safary A., et al. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine. 10:1992;S114-118.
11. McMahon B.J., Williams J., Bulkow L., et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J. Infect. Dis. 171:1995;676-679.
12. Sandman L., Davidson M., Krugman S. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. J. Infect. Dis. 171:1995;S50-52.
13. Bienzle U., Bock H.L., Kruppenbacher J.P., Hofmann F., Vogel G.E., Clemens R. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response. Vaccine. 14:1996;501-505.
14. Bovier P.A., Althaus B., Glueck R., Chippaux A., Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J. Travel. Med. 6:1999;228-233.